Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects
Executive Summary
Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.
You may also be interested in...
AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets
Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.
Medivir's Oncology Asset Purchase Seals TetraLogic's Death
Medivir, which recently reinvented itself as a solely oncology-based R&D company, is buying two programs for TetraLogic which will subsequently 'terminate all remaining employees'.